Rhenium-186 hydroxyethylidene diphosphonate for treatment of painful osseous metastases from mammary carcinoma.
Virotta
G
G
Nuclear Medicine Department, Ospedali Riuniti, Bergamo, Italy.
Medolago
G
G
Arrigoni
S
S
Butti
I
I
Bertocchi
C
C
D000328:Adult; D000368:Aged; D001792:Blood Platelets / Q000528:radiation effects; D001853:Bone Marrow / Q000528:radiation effects*; D001859:Bone Neoplasms / Q000150:complications / Q000378:metabolism / Q000532:radiotherapy* / Q000556:secondary* / Q000652:urine; D001943:Breast Neoplasms / Q000378:metabolism / Q000473:pathology* / Q000652:urine; D012968:Etidronic Acid / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007962:Leukocytes / Q000528:radiation effects; D008875:Middle Aged; D009942:Organometallic Compounds; D010146:Pain / Q000209:etiology*; D010147:Pain Measurement; D011868:Radioisotopes / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D012211:Rhenium / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016896:Treatment Outcome
D009942:Organometallic Compounds; D011868:Radioisotopes; C101598:rhenium-186 HEDP; D012211:Rhenium; D012968:Etidronic Acid